Curasight and Curium sign global radioisotope supply agreement for uTREAT® - Agreement ensures supply of non-carrier-added Lutetium-177 for uTREAT® development and commercial supply including plans for upcoming pivotal therapy trials - The agreement supports Curasight’s strategy to leverage partnerships as it progresses its uPAR theranostic solution to diagnose and treat certain types of cancer. #curasight #curium #cancer #partnership #theranostic #utreat #utrace
Curasight’s Post
More Relevant Posts
-
Bispecific ADCs have the potential to deliver enhanced efficacy over canonical ADC approaches for the same payload dose, and this is exactly what we see with ALM-401. Great to see this novel engineered Bispecific ADC progressing forward.
Almac Discovery announces the nomination of ALM-401 as a First in Class Bispecific Next Generation ADC for the treatment of refractory lung cancer to progress into pre-clinical development. Read more in our latest press release: https://hubs.li/Q02yXZyZ0
-
-
Tune in as Daejin Abidoye joins a #FierceBiotech panel to share his insights on antibody-drug conjugates (#ADCs) and how we’re working to advance novel #cancer treatment options for patients. Learn more about our work in oncology: https://bit.ly/3NtOhbc
-
-
Tune in as Daejin Abidoye joins a #FierceBiotech panel to share his insights on antibody-drug conjugates (#ADCs) and how we’re working to advance novel #cancer treatment options for patients. Learn more about our work in oncology: https://bit.ly/3NsoPTj
-
-
Keya Watkins shares her key takeaways from the 2024 Society for Immunotherapy of Cancer (SITC) conference. While there has been a lot of progress in recent years, there is much more work (and many successes) ahead. Read about the presentations she attended and where the convergence of technology and science will help us to develop new oncology treatments. https://hubs.li/Q02Z-M8y0 #SITC2024 #InnovationsTechnology #ScienceAdvancements #OncologyBreakthroughs #ConnectWithCatalyst
-
-
Tune into the webinar from SPCC below if you are interested in hearing me discuss an amazing drug development story in ALK+ lung cancer: “The story of ALK - crizotinib to lorlatinib”
💊 Ever wondered about the origins of oncology drugs and how many of them nearly never saw the light of day? “Behind every drug there is a story” is a webinar designed to teach about what it takes to develop a blockbuster in oncology. ✅ NOW available on-demand: https://lnkd.in/e8-GP_jW 🗣 Matti Aapro, Aleksandra Filipovic MD Ph.D., Graham Ferrier, PhD, Daniel Fowler #Cancer #OncologyDrugs #CancerCare
-
-
Obe-cel CAR T Therapy Achieves High Response Rates in R/R B-cell ALL: FELIX Trial Results Autolus Therapeutics MD Anderson Cancer Center FDA https://lnkd.in/e7riXFPt #ASH2024 #AutolusTherapeutics #BALL #Cancer #FDA #FELIXTrial #ObeCel #Obecabtagene #Autoleucel #OncoDaily #Oncology #R/R-Cell #B-ALL #Medcine #Health
-
-
Today is #MesotheliomaAwarenessDay. We at Verismo Therapeutics stand in solidarity with those affected by this rare and aggressive cancer. Together, we can make a difference in the fight against mesothelioma. #MesotheliomaAwarenessDay #celltherapy #VerismoTherapeutics
-
-
It's not too late to register for this week's webinar, Oncology 2050: Have We Been Thinking About the Management of Cancer in the Right Way? Join us as we dive into the future of oncology, redefining treatment strategies, advancing AI, and more. Register at https://lnkd.in/gRc_wcPh Hear from our panel of experts, including Axel Hoos, Peter Sandor, EVP, Astellas Pharma US, and Lumanity's Jeff Bockman, Viraj Parekh, and Dennis Chang. #Oncology #Cancer #CancerProgress #CancerTreatment #AIinCancerTreatment
-
Our primary #TACT #celltherapy asset targets Claudin 18.2, a molecule that becomes exposed on the surface of #solidtumors in #GastricCancer, #PancreaticCancer, and other cancer types. Learn more about the potential of #Claudin-targeting therapies: https://lnkd.in/eFC-qTRH
-
-
ASCO 2024 EMERALD (JBCRG-M06) Study A less toxic but equally effective alternative to the taxane-containing regimen, eribulin combined with Trastuzumab +Pertuzumab could be a first-line treatment of locally advanced or metastatic HER2+ Breast cancer. To Read more visit https://lnkd.in/dzB5FRzg #Breastcancer #ASCO2024 #Researchoncology